While immunotherapy monotherapy demonstrates substantial efficacy in NSCLC patients with high PD-L1 expression (tumor proportion score ≥ 50%), its benefits in PD-L1-low populations mirror those of conventional chemotherapy (26–29). The gene discussed is CD274; the disease is non-small cell lung carcinoma.